Evidence map›Paper›PMID 40733599›Full record

Trial reportViruses2025

Adrenomedullin Therapy for Moderate-to-Severe COVID-19 Pneumonia: Double-Blind Placebo-Controlled Phase 2a Trial.

Toshihiro Kita, Norio Ohmagari, Sho Saito, Hiroshi Mukae, Takahiro Takazono, Taka-Aki Nakada, Tadanaga Shimada, Yuji Hirai, Yuichiro Shindo, Kosaku Komiya and 15 more

Abstract readRandomized Controlled TrialMulticenter StudyClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Toshihiro KitaDepartment of Projects Research, Frontier Science Research Center, University of Miyazaki, Miyazaki 889-1692, Japan.ORCID 0000-0003-1903-9012
Norio OhmagariDisease Control and Prevention Center, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo 162-8655, Japan.
Sho SaitoDisease Control and Prevention Center, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo 162-8655, Japan.
Hiroshi MukaeDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8520, Japan.
Takahiro TakazonoDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8520, Japan.ORCID 0000-0002-0696-5386
Taka-Aki NakadaDepartment of Emergency and Critical Care Medicine, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.
Tadanaga ShimadaDepartment of Emergency and Critical Care Medicine, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.ORCID 0000-0002-0505-5145
Yuji HiraiDepartment of Infectious Diseases, Tokyo Medical University Hachioji Medical Center, Hachioji 193-0998, Japan.
Yuichiro ShindoDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.ORCID 0000-0002-0207-9483
Kosaku KomiyaRespiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, Oita 879-5593, Japan.ORCID 0000-0002-8679-1661
Atsushi SaitoDepartment of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo 060-8556, Japan.ORCID 0000-0003-3430-884X
Masaya YamatoDepartment of General Internal Medicine and Infectious Diseases, Rinku General Medical Center, Izumisano 598-8577, Japan.
Koichiro HommaDepartment of Emergency and Critical Care Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan.
Masaki OkamotoDepartment of Respirology, NHO Kyushu Medical Center, Fukuoka 810-0065, Japan.ORCID 0000-0002-9298-3504
Yoshihiro YamamotoDepartment of Clinical Infectious Diseases, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama 930-8555, Japan.ORCID 0000-0003-2088-8724
Yoshikazu MutohDepartment of Infectious Diseases, Tosei General Hospital, Seto 489-8642, Japan.ORCID 0000-0002-7368-3004
Chihiro HasegawaNagoya City University East Medical Center, Nagoya 464-8547, Japan.
Nobuaki MoriDepartment of General Internal Medicine and Infectious Diseases, NHO Tokyo Medical Center, Tokyo 152-8902, Japan.ORCID 0000-0002-1433-0276
Fukumi Nakamura-UchiyamaDepartment of Infectious Diseases, Tokyo Metropolitan Bokutoh Hospital, Tokyo 130-8575, Japan.
Mitsuru HondaCritical Care Center, Toho University Omori Medical Center, Tokyo 143-8540, Japan.
Keisuke TomiiDepartment of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe 650-0047, Japan.ORCID 0000-0002-3524-6217
Hiroshi IshiiDepartment of Respiratory Medicine, Fukuoka University Chikushi Hospital, Fukuoka 818-8502, Japan.ORCID 0000-0002-2143-5922
Ichiro TakajoDivision of Respirology, Rheumatology, Infectious Diseases, and Neurology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-2192, Japan.
Koji WatanabeDepartment of Projects Research, Frontier Science Research Center, University of Miyazaki, Miyazaki 889-1692, Japan.
Kazuo KitamuraDepartment of Projects Research, Frontier Science Research Center, University of Miyazaki, Miyazaki 889-1692, Japan.ORCID 0000-0002-5124-9549

Funding

Japan Agency for Medical Research and Development 20fk0108275h0001, 20fk0108504h0001, and 21fk0108484h0001
6 · The paper itself

Abstract

Adrenomedullin (AM) is a bioactive peptide that is strongly induced during severe inflammation, including pneumonia and sepsis, and serves as an organ-protective factor. The plasma concentration of AM is markedly increased in the novel coronavirus disease COVID-19 and is closely related to the severity of the disease and prognosis of patients. We performed two investigator-initiated trials to evaluate the efficacy and safety of AM in patients with moderate-to-severe COVID-19. This multicenter, double-blind, placebo-controlled phase-2a trial evaluated COVID-19 patients with severe (

Indexed as

AdrenomedullinCOVID-19 Drug TreatmentAdultAgedCOVID-19Double-Blind MethodFemaleHumansJapanMaleMiddle AgedRespiration, ArtificialSARS-CoV-2Severity of Illness IndexTreatment OutcomeAdrenomedullinadrenomedullinCOVID-19Japanesemechanical ventilationphase 2a clinical trialpneumonia

Identifiers

PMID40733599
PMCPMC12299281

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.